[96a5a0]: / output / allTrials / identified / NCT06135194_identified.json

Download this file

260 lines (260 with data), 11.9 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
{
"info": {
"nct_id": "NCT06135194",
"official_title": "Efficacy and Safety of T-Dxd in the Treatment of HER2-positive Breast Cancer With Brain Metastases After Prior Pyrotinib Treatment",
"inclusion_criteria": "(1) Women ≥18 years of age :(2) pathological diagnosis of HER2-positive breast cancer, defined as positive immunohistochemistry detection (+++) or FISH(Fluorescent In Situ Hybridization); (3) Imaging evidence of brain metastases; (4) Progression of brain metastases after prior treatment with pyrotinib, defined as progression of new or pre-existing brain metastases during treatment with pyrotinib; (5)ECOG score ≤3 points; (6) The efficacy of T-DXd should be evaluated at least once after treatment; (7) Bone marrow and organ functions are basically normal; (8) Complete medical records\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
"exclusion_criteria": "* Has uncontrolled or significant cardiovascular disease\n* Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/ pneumonitis that cannot be ruled out by imaging at screening\n* Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "(1) Women ≥18 years of age :(2) pathological diagnosis of HER2-positive breast cancer, defined as positive immunohistochemistry detection (+++) or FISH(Fluorescent In Situ Hybridization); (3) Imaging evidence of brain metastases; (4) Progression of brain metastases after prior treatment with pyrotinib, defined as progression of new or pre-existing brain metastases during treatment with pyrotinib; (5)ECOG score ≤3 points; (6) The efficacy of T-DXd should be evaluated at least once after treatment; (7) Bone marrow and organ functions are basically normal; (8) Complete medical records",
"criterions": [
{
"exact_snippets": "Women ≥18 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
},
{
"exact_snippets": "pathological diagnosis of HER2-positive breast cancer",
"criterion": "HER2-positive breast cancer",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
},
{
"exact_snippets": "positive immunohistochemistry detection (+++) or FISH(Fluorescent In Situ Hybridization)",
"criterion": "HER2-positive breast cancer",
"requirements": [
{
"requirement_type": "detection method",
"expected_value": [
"immunohistochemistry (+++)",
"FISH (Fluorescent In Situ Hybridization)"
]
}
]
},
{
"exact_snippets": "Imaging evidence of brain metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "imaging evidence",
"expected_value": true
}
]
},
{
"exact_snippets": "Progression of brain metastases after prior treatment with pyrotinib",
"criterion": "progression of brain metastases",
"requirements": [
{
"requirement_type": "after treatment with pyrotinib",
"expected_value": true
}
]
},
{
"exact_snippets": "ECOG score ≤3 points",
"criterion": "ECOG score",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "points"
}
}
]
},
{
"exact_snippets": "The efficacy of T-DXd should be evaluated at least once after treatment",
"criterion": "efficacy evaluation of T-DXd",
"requirements": [
{
"requirement_type": "evaluation frequency",
"expected_value": "at least once after treatment"
}
]
},
{
"exact_snippets": "Bone marrow and organ functions are basically normal",
"criterion": "bone marrow and organ functions",
"requirements": [
{
"requirement_type": "normality",
"expected_value": "basically normal"
}
]
},
{
"exact_snippets": "Complete medical records",
"criterion": "medical records",
"requirements": [
{
"requirement_type": "completeness",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": "FEMALE"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 80 Years",
"criterions": [
{
"exact_snippets": "maximum age of 80 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 80,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Has uncontrolled or significant cardiovascular disease",
"criterions": [
{
"exact_snippets": "uncontrolled or significant cardiovascular disease",
"criterion": "cardiovascular disease",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
},
{
"requirement_type": "severity",
"expected_value": "significant"
}
]
}
]
},
{
"line": "* Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/ pneumonitis that cannot be ruled out by imaging at screening",
"criterions": [
{
"exact_snippets": "Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids",
"criterion": "history of interstitial lung disease (ILD)/pneumonitis",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": "required steroids"
}
]
},
{
"exact_snippets": "has current ILD/pneumonitis",
"criterion": "current interstitial lung disease (ILD)/pneumonitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "suspected ILD/ pneumonitis that cannot be ruled out by imaging at screening",
"criterion": "suspected interstitial lung disease (ILD)/pneumonitis",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "cannot be ruled out by imaging at screening"
}
]
}
]
},
{
"line": "* Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study",
"criterions": [
{
"exact_snippets": "any medical history or condition",
"criterion": "medical history or condition",
"requirements": [
{
"requirement_type": "appropriateness for the study",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}